

Disclosures

Personal Commercial (8)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Array Biopharma	Research/Research Grants <i>‡ Trial of p38 inhibitor in lamin associated cardiomyopathy</i>	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>
Atlas Ventures Development Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Other</i>
Gilead Sciences, Inc.	Research/Research Grants	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Harvard Medical School	Other	Modest (< \$5,000)	<i>Other</i>
Merck & Co., Inc.	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Pfizer	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Sanofi-Aventis	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>

Personal Non-Commercial (4)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Burroughs Wellcome Foundation	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Harvard Stem Cell Institute	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology Congenital Heart Disease and Pediatric Cardiology</i>
Muscular Dystrophy Association	Research/Research Grants	Significant (>= \$5,000)	<i>Congenital Heart Disease and Pediatric Cardiology</i>
NIH Research Grants	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (4)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2015	Aortic disease	Defendant	Decision making and responsibility with regard to aortic root surveillance which eventually led to fatal dissection.	Modest (< \$5,000)
2015	Diagnosis of myocardial abnormality	Plaintiff	Misinterpretation of EKG	Modest (< \$5,000)
2015	Inherited heart disease	Defendant	Complications of sepsis in inherited heart disease	Modest (< \$5,000)

Agreement

Certified Education Attestation | Signed on 2/7/2016

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 2/7/2016

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 2/7/2016

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 2/7/2016

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.